{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:38Z","timestamp":1753891898524,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Everolimus has been approved in China for adult patients with TSC-AML (tuberous sclerosis associated renal angiomyolipomas) not requiring immediate surgery and has been previously shown to be an effective treatment option for TSC-AML in the Chinese population<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is an open label, single arm, multi-center Phase IV post-approval commitment study to further assess the safety and efficacy of everolimus in patients with TSC-AML who do not require immediate surgical intervention. The primary outcome was to evaluate the safety of everolimus while the secondary outcome was to evaluate AML response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with everolimus was associated with a clinically meaningful best overall AML response rate of 70% (95% CI: 53.5, 83.4). Of the 38 evaluable patients, 37 (97%) patients experienced a reduction in the sum of volumes of target angiomyolipoma lesions relative to baseline. At Week 12 (n=38), the median percentage change in sum of target AML volume was \u221256.60%, which further changed by -59.96% at Week 24 (n=38), and by \u221264.41% at Week 48 (n=22). Throughout the study, renal function remained relatively stable. Patients with TSC associated lymphangiomyomatosis (LAM) (N=13) demonstrated a lower than expected rate of decline in pulmonary function tests (PFTs). Everolimus was generally well tolerated with no significant safety findings in Chinese patients. Most of the adverse events were of grade 1-2, and manageable with appropriate dose adjustments and supportive therapies. There were no treatment discontinuation due to AE and no treatment death was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Based on the efficacy and safety data presented in this study, the overall clinical benefit\/risk assessment further supports the use of everolimus as a viable treatment option for Chinese patients with TSC-AML.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.871723","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T18:54:29Z","timestamp":1656960869000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Multi-Centric Study Assessing Safety and Efficacy of Everolimus in Adult Chinese Patients With Tuberous Sclerosis Complex Associated Renal Angiomyolipomas"],"prefix":"10.3389","volume":"12","author":[{"given":"Wenda","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiquan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1055\/s-0030-1269906","article-title":"Tuberous Sclerosis Complex: Neurological, Renal and Pulmonary Manifestations","volume":"41","author":"Franz","year":"2010","journal-title":"Neuropediatrics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.10.013","article-title":"Tuberous Sclerosis Complex-Associated Angiomyolipomas: Focus on mTOR Inhibition","volume":"59","author":"Budde","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous Sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra055323","article-title":"The Tuberous Sclerosis Complex","volume":"3555","author":"Crino","year":"2006","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0898","article-title":"Lymphangioleiomyomatosis: A Clinical Update","volume":"133","author":"McCormack","year":"2008","journal-title":"Chest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00838.x","article-title":"Renal Angiomyolipomata","volume":"66","author":"Bissler","year":"2004","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph1033","article-title":"A Case of Tuberous Sclerosis Complex That Progressed to End-Stage Renal Disease","volume":"5","author":"Sarraf","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1148\/radiol.2251011477","article-title":"Renal Angiomyolipoma: Relationships Between Tumor Size, Aneurysm Formation, and Rupture","volume":"225","author":"Yamakado","year":"2002","journal-title":"Radiology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous Sclerosis Complex Surveillance and Management:Recommendations of the 2012 International Tuberous SclerosisComplex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2021.07.010","article-title":"Beyond the Guidelines: How We Can Improve Healthcare for People With Tuberous Sclerosis Complex Around the World","volume":"123","author":"Stuart","year":"2021","journal-title":"Pediatr Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR Signaling in Growth Control and Disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for Angiomyolipoma Associated With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (EXIST-2): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for Renal Angiomyolipoma in Patients With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis: Extension of a Randomized Controlled Trial","volume":"31","author":"Bissler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus Long-Term Use in Patients With Tuberous Sclerosis Complex: Four-Year Year Update of the EXIST-2 Study","volume":"12","author":"Bissler","year":"2017","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-018-0781-y","article-title":"Assessing the Outcomes of Everolimus on Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex in China: A Two Years Trial","volume":"13","author":"Cai","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404","article-title":"The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","article-title":"Confidence Interval for the Median Survival Time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13023-017-0581-9","article-title":"Management of Everolimus-Associated Adverse Events in Patients With Tuberous Sclerosis Complex: A Practical Guide","volume":"12","author":"Davies","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0340","article-title":"Evaluation of Miracle Mouthwash Plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study","volume":"24","author":"Jones","year":"2019","journal-title":"Oncologist"},{"key":"B21","doi-asserted-by":"publisher","first-page":"300891620915786","DOI":"10.1177\/0300891620915786","article-title":"Use of a Natural Multicomponent Mouthwash Plus Oral Hygiene vs Oral Hygiene Alone to Prevent Everolimus-Induced Stomatitis: The STOP Multicenter, Randomized Trial","volume":"3","author":"Porta","year":"2020","journal-title":"Tumori"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00972","article-title":"Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas","volume":"11","author":"Kingswood","year":"2020","journal-title":"Front Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1016\/S1569-9056(14)60313-4","article-title":"Real-World Assessment of Renal Involvement in Tuberous Sclerosis Complex (TSC) Patients in the United Kingdom (Uk)","volume":"13","author":"Kingswood","year":"2014","journal-title":"Eur Urol Suppl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy132","article-title":"Effect of Everolimus on Renal Function in Patients With Tuberous Sclerosis Complex: Evidence From EXIST-1 and EXIST-2","volume":"34","author":"Bissler","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00423.x","article-title":"Gonadal Impact of Target of Rapamycin Inhibitors (Sirolimus and Everolimus) in Male Patients: An Overview","volume":"20","author":"Huyghe","year":"2007","journal-title":"Transpl Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.03.012","article-title":"Pneumonitis Associated With mTOR Inhibitors Therapy in Patients With Metastatic Renal Cell Carcinoma: Incidence, Radiographic Findings and Correlation With Clinical Outcome","volume":"48","author":"Dabydeen","year":"2012","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13428","article-title":"Intermittent Everolimus Administration for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex","volume":"24","author":"Hatano","year":"2017","journal-title":"Int J Urol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jim-2018-000865","article-title":"Continuous Low-Dose Everolimus Shrinkage Tuberous Sclerosis Complex-Associated Renal Angiomyolipoma: A 48-Month Follow-Up Study","author":"Wei","year":"2018","journal-title":"J Investig Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13023-021-01913-2","article-title":"Sequential Everolimus for Angiomyolipoma Associated With Tuberous Sclerosis Complex: A Prospective Cohort Study","volume":"16","author":"Gu","year":"2021","journal-title":"Orphanet J Rare Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.871723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T18:54:32Z","timestamp":1656960872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.871723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":30,"alternative-id":["10.3389\/fonc.2022.871723"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.871723","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"article-number":"871723"}}